Servier Completes Acquisition of Day One Biopharmaceuticals
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 23 2026
0mins
Source: PRnewswire
- Acquisition Completed: Servier has successfully acquired all outstanding shares of Day One Biopharmaceuticals at $21.50 per share, which not only strengthens Servier's leadership in low-grade glioma but also expands its market share in oncology.
- Strategic Goal Advancement: Servier's President, Olivier Laureau, stated that this acquisition is a significant step towards their 2030 ambition to enhance their position in rare cancers, particularly in pediatric low-grade glioma.
- Portfolio Enhancement: Day One's portfolio includes the FDA-approved OJEMDATM (tovorafenib), which is already marketed in the U.S. and licensed to Ipsen outside the U.S., further enriching Servier's oncology product line.
- R&D Capability Improvement: The acquisition will integrate Day One's scientific and clinical capabilities, enhancing Servier's ability to develop innovative therapies aimed at providing meaningful treatments for children and families affected by rare cancers.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
